Payment overview · 2025
General Payments
$74.06
3 reported records · 3 companies
Healthcare provider profile · identity verified
James P Weaver, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ASHEVILLE, NC · NPI 1083608210
Verified facts
What the public records show
CMS Open Payments records show James P Weaver, MD received $74.06 in general payments during 2025 across 3 reported records.
Novo Nordisk Inc accounted for 58.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $43.61 | 58.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.32 | 20.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.13 | 20.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $74.06 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $43.61 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.32 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.32 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 193 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
79 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
193 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 783 | 212 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 541 | 162 |
| Amlodipine Besylate | Amlodipine Besylate | 523 | 152 |
| Levothyroxine Sodium | Levothyroxine Sodium | 491 | 130 |
| Losartan Potassium | Losartan Potassium | 424 | 117 |
| Metoprolol Succinate | Metoprolol Succinate | 360 | 97 |
| Hydrochlorothiazide | Hydrochlorothiazide | 275 | 80 |
| Omeprazole | Omeprazole | 259 | 72 |
| Valsartan | Valsartan | 248 | 77 |
| Trazodone Hcl | Trazodone Hcl | 243 | 69 |
| Lisinopril | Lisinopril | 216 | 64 |
| Gabapentin | Gabapentin | 213 | 57 |
| Escitalopram Oxalate | Escitalopram Oxalate | 203 | 59 |
| Metformin Hcl | Metformin Hcl | 195 | 61 |
| Telmisartan | Telmisartan | 195 | 57 |
| Eliquis | Apixaban | 193 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 193 | 48 |
| Alendronate Sodium | Alendronate Sodium | 192 | 50 |
| Simvastatin | Simvastatin | 192 | 55 |
| Famotidine | Famotidine | 178 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 170 | 58 |
| Furosemide | Furosemide | 157 | 41 |
| Jardiance | Empagliflozin | 152 | 32 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 148 | 35 |
| Potassium Chloride | Potassium Chloride | 145 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 141 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 124 | 38 |
| Spironolactone | Spironolactone | 115 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 114 | 35 |
| Xarelto | Rivaroxaban | 109 | 30 |
| Celecoxib | Celecoxib | 106 | 36 |
| Sertraline Hcl | Sertraline Hcl | 105 | 27 |
| Ezetimibe | Ezetimibe | 100 | 30 |
| Metformin Hcl Er | Metformin Hcl | 98 | 30 |
| Atenolol | Atenolol | 95 | 27 |
| Montelukast Sodium | Montelukast Sodium | 93 | 25 |
| Allopurinol | Allopurinol | 91 | 23 |
| Chlorthalidone | Chlorthalidone | 87 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 43 |
| Irbesartan | Irbesartan | 84 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 83 | 23 |
| Lorazepam | Lorazepam | 83 | 25 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 81 | 65 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 80 | 24 |
| Alprazolam | Alprazolam | 79 | 15 |
| Ozempic | Semaglutide | 79 | 19 |
| Tramadol Hcl | Tramadol Hcl | 74 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 28 |
| Finasteride | Finasteride | 64 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 64 | 19 |
| Bupropion Xl | Bupropion Hcl | 63 | 19 |
| Carvedilol | Carvedilol | 63 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 18 |
| Buspirone Hcl | Buspirone Hcl | 61 | 17 |
| Propranolol Hcl | Propranolol Hcl | 61 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 16 |
| Synthroid | Levothyroxine Sodium | 59 | 19 |
| Glipizide Er | Glipizide | 58 | 17 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 54 | 54 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 53 | 12 |
| Meloxicam | Meloxicam | 53 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 52 | suppressed |
| Januvia | Sitagliptin Phosphate | 51 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 49 | 18 |
| Clonazepam | Clonazepam | 47 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 17 |
| Valacyclovir | Valacyclovir Hcl | 46 | 19 |
| Glimepiride | Glimepiride | 42 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 38 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Naproxen | Naproxen | 36 | 12 |
| Prednisone | Prednisone | 36 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Lansoprazole | Lansoprazole | 34 | 11 |
| Repatha Sureclick | Evolocumab | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Diazepam | Diazepam | 31 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Eszopiclone | Eszopiclone | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 24 | suppressed |
| Estradiol | Estradiol | 23 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Invokana | Canagliflozin | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Azithromycin | Azithromycin | 16 | 16 |
| Tramadol Hcl Er | Tramadol Hcl | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 15 |
| Nitroglycerin | Nitroglycerin | 15 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 12 |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 12 |
| Estradiol (Twice Weekly) | Estradiol | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Livalo | Pitavastatin Calcium | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $74.06 · 3 records | Novo Nordisk Inc | ELIQUIS, NURTEC ODT, OTEZLA, REPATHA, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error